Elizabeth Gasser compensation by year
TANDEM DIABETES CARE Summary Compensation Table · all 5 fiscal years held| Component | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Salary | $424,360 | $437,091 | $437,091 | $450,203 | $463,710 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $424,312 | $732,050 | $707,727 | $1,307,627 | $1,035,730 |
| Option awards | $424,335 | $360,598 | $0 | $0 | $0 |
| Non-equity incentive | $339,403 | $132,628 | $98,345 | $239,863 | $240,158 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $878 | $37,110 | $7,478 | $7,778 | $8,346 |
| Total | $1,613,288 | $1,699,477 | $1,250,641 | $2,005,471 | $1,747,944 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: TANDEM DIABETES CARE INC DEF 14A filed April 7, 2026, accession 0001438133-26-000034, and prior-year filings. Open the filing on EDGAR.
How this page was built: the TANDEM DIABETES CARE INC filed document, accession 0001438133-26-000034. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 23,002 | $505,584 | — |
| PSU | 23,000 | $505,540 | — |
| PSU | 13,160 | $289,257 | — |
| RSU | 6,581 | $144,650 | — |
| RSU | 3,006 | $66,072 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in TANDEM DIABETES CARE INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments TANDEM DIABETES CARE discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $1,112,904 | $716,306 | — | $1,829,210 |
| Change in control and resignation for good reason | $1,112,904 | $716,306 | — | $1,829,210 |
Per the Potential Payments Upon Termination or Change in Control table in TANDEM DIABETES CARE INC's FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
TANDEM DIABETES CARE’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| John Sheridan | President and Chief Executive Officer | $6,858,503 |
| Mark Novara | Executive Vice President and Chief Commercial Officer | $2,204,612 |
| Leigh Vosseller | Executive Vice President, Chief Financial Officer and Treasurer | $2,181,894 |
| Elizabeth Gasser · this page | Executive Vice President and Chief Strategy and Product Officer | $1,747,944 |
| Shannon Hansen | Executive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary | $1,747,901 |
The full TANDEM DIABETES CARE compensation record
free company briefThis page is one person within TANDEM DIABETES CARE's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the TANDEM DIABETES CARE proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order TANDEM DIABETES CARE's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are TANDEM DIABETES CARE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TNDM
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.